• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CRS/HIPEC 术中膈肌腹膜切除术和全层切除术可提高细胞减灭术的完全性切除率,且呼吸并发症发生率较低。

Diaphragmatic Peritonectomy and Full-Thickness Resection in CRS/HIPEC May Allow Higher Completeness of Cytoreduction Rates with a Low Rate of Respiratory Complications.

机构信息

General and Digestive Surgery Department, University Hospital Son Espases, Palma De Mallorca, Spain.

Health Research Institute of Balearic Islands, Palma De Mallorca, Spain.

出版信息

Ann Surg Oncol. 2021 Aug;28(8):4676-4682. doi: 10.1245/s10434-020-09505-3. Epub 2021 Jan 6.

DOI:10.1245/s10434-020-09505-3
PMID:33409735
Abstract

BACKGROUND

Cytoreductive surgery (CRS) provides a survival benefit when achieved without residual disease. As diaphragm is frequently affected in peritoneal malignancies, complete cytoreduction often requires surgical techniques over the diaphragm. The purpose of the study was to assess diaphragmatic resection impact on cytoreduction completeness, morbidity and mortality compared to less aggressive diaphragmatic peritonectomy in CRS and hyperthermic intraperitoneal chemotherapy (HIPEC) settings.

MATERIALS AND METHODS

Patients with peritoneal carcinomatosis and supramesocolic disease undergoing CRS/HIPEC from 2011 to 2019 were included in a prospectively collected database. We compared patients who underwent full-thickness diaphragmatic resection (DR) and diaphragmatic peritonectomy (DP). Epidemiological and clinical data, morbidity, and mortality within 90 days of surgery were documented.

RESULTS

232 patients were initially selected. Inclusion criteria were met by 88 procedures. DR was performed on 32 patients and DP on 56. Number of resected organs was 5.21 in the DR cohort vs. 3.57 in the DP cohort (p<0.0001). Rate of Peritoneal Cancer Index (PCI) score >14 was higher in the DR group (75%) than in the DP group (50.9%) (p=0.027). Tumor invasion of diaphragmatic muscle after DR was confirmed in 89.3% patients. Postoperative pleural effusion was observed in 28 patients (50%) in the DP group and in 17 (53.1%) in the DR group.

CONCLUSIONS

CRS/HIPEC requires specific surgical techniques over the diaphragm to achieve complete cytoreduction. As diaphragmatic muscle invasion is frequent, full-thickness resection may allow a cytoreduction completeness increase without an increased morbidity. Pleural drains are not systematically required as these procedures show low incidence of major respiratory complications.

摘要

背景

在没有残留疾病的情况下,细胞减灭术(CRS)可提供生存获益。由于膈膜在腹膜恶性肿瘤中经常受到影响,因此完全细胞减灭术通常需要在膈膜上使用手术技术。本研究的目的是评估膈膜切除术对细胞减灭术完成度、发病率和死亡率的影响,与 CRS 和腹腔热灌注化疗(HIPEC)中不太激进的膈膜腹膜切除术相比。

材料和方法

从 2011 年到 2019 年,纳入了在腹膜恶性肿瘤和上肠系膜疾病中接受 CRS/HIPEC 的患者,纳入了一个前瞻性收集的数据库。我们比较了接受全层膈膜切除术(DR)和膈膜腹膜切除术(DP)的患者。记录了手术 90 天内的流行病学和临床数据、发病率和死亡率。

结果

最初选择了 232 例患者。符合纳入标准的 88 例手术。32 例患者接受了 DR,56 例患者接受了 DP。DR 组切除的器官数为 5.21 个,DP 组为 3.57 个(p<0.0001)。DR 组的腹膜癌症指数(PCI)评分>14 的比例(75%)高于 DP 组(50.9%)(p=0.027)。DR 后膈膜肌肉的肿瘤侵犯在 89.3%的患者中得到证实。DP 组有 28 例(50%)和 DR 组有 17 例(53.1%)患者术后出现胸腔积液。

结论

CRS/HIPEC 需要在膈膜上使用特定的手术技术来实现完全细胞减灭术。由于膈膜肌肉侵犯较为常见,因此全层切除可能会增加细胞减灭术的完成度,而不会增加发病率。由于这些手术的主要呼吸系统并发症发生率较低,因此不需要系统地放置胸腔引流管。

相似文献

1
Diaphragmatic Peritonectomy and Full-Thickness Resection in CRS/HIPEC May Allow Higher Completeness of Cytoreduction Rates with a Low Rate of Respiratory Complications.CRS/HIPEC 术中膈肌腹膜切除术和全层切除术可提高细胞减灭术的完全性切除率,且呼吸并发症发生率较低。
Ann Surg Oncol. 2021 Aug;28(8):4676-4682. doi: 10.1245/s10434-020-09505-3. Epub 2021 Jan 6.
2
Diaphragmatic Peritoneal Stripping Versus Full-Thickness Resection in CRS/HIPEC: Is There a Difference?CRS/HIPEC 中膈肌腹膜剥离与全层切除术:有区别吗?
Ann Surg Oncol. 2020 Jan;27(1):250-258. doi: 10.1245/s10434-019-07797-8. Epub 2019 Sep 9.
3
Stapled Full-Thickness Diaphragm Resection: A Novel Approach to Diaphragmatic Resection in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.吻合器全层膈肌切除术:细胞减灭术联合腹腔内热灌注化疗中膈肌切除术的新方法
J Am Coll Surg. 2022 Jun 1;234(6):e1-e6. doi: 10.1097/XCS.0000000000000152. Epub 2022 Mar 8.
4
Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).膈肌切除术和胸腔内化疗灌注对经细胞减灭术(CRS)和腹腔热灌注化疗(HIPEC)治疗的腹膜表面疾病预后的意义。
Ann Surg Oncol. 2014 Dec;21(13):4226-31. doi: 10.1245/s10434-014-3891-3. Epub 2014 Jul 18.
5
Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on patients with diaphragmatic involvement.细胞减灭术及腹腔内热灌注化疗对伴有膈肌受累患者的疗效
Ann Surg Oncol. 2015 May;22(5):1639-44. doi: 10.1245/s10434-014-4083-x. Epub 2014 Sep 13.
6
Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy.识别膈肌细胞减灭术和术中高热腹腔内化疗后呼吸并发症的发生率。
Clin Transl Oncol. 2020 Jun;22(6):852-859. doi: 10.1007/s12094-019-02195-8. Epub 2019 Aug 7.
7
Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.新辅助化疗联合腹腔热灌注化疗治疗结直肠腹膜转移患者的安全性和有效性:一项回顾性研究。
World J Surg Oncol. 2021 May 17;19(1):151. doi: 10.1186/s12957-021-02255-w.
8
Feasibility of diaphragmatic interventions in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: A 20-year experience.腹腔热灌注化疗治疗腹膜转移癌的细胞减灭术中膈肌干预的可行性:20 年经验。
Eur J Surg Oncol. 2021 Jan;47(1):143-148. doi: 10.1016/j.ejso.2020.08.016. Epub 2020 Aug 26.
9
Outcomes Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy with and without Diaphragmatic Resection in Patients with Peritoneal Metastases.腹膜转移患者接受细胞减灭术联合热灌注化疗伴或不伴膈肌切除术后的结局
Ann Surg Oncol. 2022 Feb;29(2):873-882. doi: 10.1245/s10434-021-10669-9. Epub 2021 Sep 21.
10
Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.复发性腹膜癌患者的重复细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)
World J Surg Oncol. 2016 Feb 24;14(1):42. doi: 10.1186/s12957-016-0804-x.

引用本文的文献

1
Evaluating Respiratory Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Subphrenic Peritonectomy Versus Full Thickness Diaphragm Resection.评估减瘤手术及热灌注化疗联合膈下腹膜切除术与全层膈肌切除术治疗后的呼吸并发症
J Surg Oncol. 2025 Aug;132(2):260-266. doi: 10.1002/jso.70003. Epub 2025 Jun 16.
2
Reflections on the role of diaphragmatic resection techniques in cytoreductive surgery: indications, outcomes, and unresolved questions.关于膈肌切除技术在肿瘤细胞减灭术中的作用的思考:适应证、结果及未解决的问题
Langenbecks Arch Surg. 2025 Mar 22;410(1):102. doi: 10.1007/s00423-025-03646-3.
3

本文引用的文献

1
Secondary surgical cytoreduction needs to be assessed taking into account surgical technique, completeness of cytoreduction, and extent of disease.需要考虑手术技术、减瘤术的完整性和疾病的范围来评估二次手术的减瘤效果。
World J Surg Oncol. 2020 May 11;18(1):92. doi: 10.1186/s12957-020-01853-4.
2
Diaphragmatic Peritoneal Stripping Versus Full-Thickness Resection in CRS/HIPEC: Is There a Difference?CRS/HIPEC 中膈肌腹膜剥离与全层切除术:有区别吗?
Ann Surg Oncol. 2020 Jan;27(1):250-258. doi: 10.1245/s10434-019-07797-8. Epub 2019 Sep 9.
3
Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy.
Diaphragmatic stripping versus full-thickness diaphragmatic resection in cytoreductive surgery: a meta-analysis of the current evidence.
减瘤手术中膈肌剥离与全层膈肌切除的比较:当前证据的荟萃分析
Langenbecks Arch Surg. 2025 Jan 25;410(1):50. doi: 10.1007/s00423-025-03611-0.
4
Challenges following CRS and HIPEC surgery in cancer patients with peritoneal metastasis: a comprehensive review of clinical outcomes.伴有腹膜转移的癌症患者接受细胞减灭术和热灌注化疗手术后面临的挑战:临床结局的全面综述
Front Surg. 2024 Dec 2;11:1498529. doi: 10.3389/fsurg.2024.1498529. eCollection 2024.
5
Predictive value of C-reactive protein levels for the early and later detection of postoperative complications after cytoreductive surgery and HIPEC.C反应蛋白水平对减瘤手术及腹腔热灌注化疗术后并发症早期及后期检测的预测价值
Front Oncol. 2022 Oct 25;12:943522. doi: 10.3389/fonc.2022.943522. eCollection 2022.
识别膈肌细胞减灭术和术中高热腹腔内化疗后呼吸并发症的发生率。
Clin Transl Oncol. 2020 Jun;22(6):852-859. doi: 10.1007/s12094-019-02195-8. Epub 2019 Aug 7.
4
Long term survival and perioperative propensity score matched outcomes of diaphragmatic resections compared to stripping in cytoreductive surgery + intra-peritoneal chemotherapy.在细胞减灭术+腹腔内化疗中,与剥离相比,膈切除术的长期生存和围手术期倾向评分匹配结果。
Am J Surg. 2020 Apr;219(4):673-680. doi: 10.1016/j.amjsurg.2019.06.018. Epub 2019 Jun 23.
5
European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery.欧洲妇科肿瘤学会(ESGO)卵巢癌手术指南。
Int J Gynecol Cancer. 2017 Sep;27(7):1534-1542. doi: 10.1097/IGC.0000000000001041.
6
Experiences with the standardized classification of surgical complications (Clavien-Dindo) in general surgery patients.普通外科患者手术并发症标准化分类(Clavien-Dindo)的经验。
Eur Surg. 2018;50(6):256-261. doi: 10.1007/s10353-018-0551-z. Epub 2018 Jul 24.
7
Goal-directed therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a prospective observational study.腹腔内热灌注化疗下细胞减灭术的目标导向治疗:一项前瞻性观察研究。
Clin Transl Oncol. 2019 Apr;21(4):451-458. doi: 10.1007/s12094-018-1944-y. Epub 2018 Sep 14.
8
A collaborative surgical approach to upper and lower abdominal cytoreductive surgery in ovarian cancer.一种针对卵巢癌上下腹部肿瘤细胞减灭术的联合手术方法。
J Surg Oncol. 2018 Jul;118(1):121-126. doi: 10.1002/jso.25120. Epub 2018 Jun 7.
9
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.腹腔内热灌注化疗治疗卵巢癌。
N Engl J Med. 2018 Jan 18;378(3):230-240. doi: 10.1056/NEJMoa1708618.
10
In Pursuit of Optimal Cytoreduction in Ovarian Cancer Patients: The Role of Surgery and Surgeon.追求卵巢癌患者的最佳肿瘤细胞减灭术:手术及外科医生的作用
J Obstet Gynaecol India. 2009 May-Jun;59(3):209-216.